Swiss biotech Vandria SA, a company developing small molecule drugs to treat age-related and chronic diseases, announced the second closing of its Series A financing bringing the final amount raised to date to $30.7M (CHF28.3M). Hevolution Foundation and Dolby Family Ventures joined the lead founding venture investor ND Capital. Reporting rapid progress, the startup has also secured CHF 4.2M from Innosuisse and Eurostars.
